Lab
Center for Molecular Cancer Diagnostics, INC
Center for Molecular Cancer Diagnostics, INC was paid $4.65M by Medicaid between Jan 2020 and Nov 2024, across 64 billing codes. Its largest line is 87798, Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism — 30% of everything it billed.
33Billing provider infoCENTER FOR MOLECULAR CANCER DIAGNOSTICS, INC
MENTOR, OH 44060
MENTOR, OH 44060
33aNPI1316378789assigned 12/10/2013
33bProvider typeClinical Medical Laboratory
28Total paid$4.65M
24GClaims131,392
24DCodes billed64
24AFirst – last monthJan 2020 – Nov 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Ohio
Rank by total paid#25 of 116
Median peer was paid$313K
This provider vs. median15×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 9,692 | $621K | |
| 2021 | 43,087 | $1.68M | |
| 2022 | 46,527 | $1.58M | |
| 2023 | 23,891 | $647K | |
| 2024incomplete | 8,195 | $113K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 30% | 10,236 | 8,820 | $1.41M |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 25% | 18,891 | 14,982 | $1.18M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 13% | 2,634 | 2,439 | $611K |
| 87631 | 3.8% | 3,140 | 2,866 | $175K | |
| 87481 | 3.7% | 4,777 | 4,122 | $170K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 3.2% | 11,327 | 10,043 | $151K |
| 87641 | 2.4% | 8,401 | 7,236 | $112K | |
| 87653 | 2.4% | 9,860 | 8,108 | $112K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.9% | 7,945 | 6,327 | $86K |
| 87486 | 1.4% | 5,351 | 4,247 | $64K | |
| 87581 | 1.4% | 5,339 | 4,238 | $63K | |
| 87498 | 1.1% | 4,639 | 3,558 | $53K |
52 more codes
| 87541 | 1.1% | 4,588 | $52K | |
| 87496 | 1.1% | 4,522 | $51K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 2,512 | $49K |
| 87529 | <1% | 1,626 | $44K | |
| 87500 | <1% | 3,581 | $37K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,887 | $36K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,529 | $36K |
| 87150 | <1% | 286 | $30K | |
| 87186 | <1% | 2,353 | $23K | |
| 87640 | <1% | 1,943 | $16K | |
| 87532 | <1% | 1,687 | $14K | |
| 87563 | <1% | 1,878 | $13K | |
| 81000 | <1% | 590 | $11K | |
| 87511 | <1% | 1,368 | $10K | |
| 87507 | <1% | 324 | $6K | |
| 87556 | <1% | 423 | $6K | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 232 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 978 | $4K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 124 | $4K |
| 87625 | <1% | 204 | $4K | |
| 87088 | <1% | 413 | $3K | |
| 87493 | <1% | 237 | $2K | |
| 87070 | <1% | 172 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 60 | $1K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 65 | $1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 47 | $1K |
| 84311 | <1% | 91 | $435.44 | |
| 87040 | <1% | 134 | $378.12 | |
| 82140 | <1% | 429 | $284.29 | |
| 84134 | <1% | 224 | $252.51 | |
| 80053 | Comprehensive metabolic panel | <1% | 245 | $207.28 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 430 | $189.25 |
| 82570 | <1% | 118 | $133.69 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 100 | $125.54 |
| 82977 | <1% | 189 | $107.57 | |
| 82248 | <1% | 225 | $89.87 | |
| 82044 | <1% | 27 | $86.75 | |
| 83722 | <1% | 32 | $82.05 | |
| 84580 | <1% | 79 | $76.95 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 190 | $67.96 |
| 82247 | <1% | 90 | $63.50 | |
| 82043 | <1% | 81 | $56.24 | |
| 82010 | <1% | 79 | $53.53 | |
| 82945 | <1% | 79 | $43.65 | |
| 83986 | <1% | 78 | $40.13 | |
| 84156 | <1% | 79 | $37.90 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 86 | $37.59 |
| 80061 | Lipid panel | <1% | 34 | $32.13 |
| 84481 | <1% | 16 | $23.41 | |
| 81003 | <1% | 27 | $19.81 | |
| 83069 | <1% | 46 | $18.44 | |
| 84439 | <1% | 15 | $8.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHAN, YUAN (MEDICAL DIRECTOR)